Jul 09,2024 TOP STORY

Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution

Roche announced today that it has received the CE Mark for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution with 14-day wear time. This significant milestone paves the way for the solution to be made available to people living with type 1 and type 2 diabetes over the age of 18 on flexible insulin therapy. Every five minutes, the Accu-Chek SmartGuide CGM sensor sends glucose values measured in real time to the Accu-Chek SmartGuide app. The Accu-Chek SmartGuide Predict app then utilises those glucose values and other available information to detect glucose patterns and predict future glucose levels. Its integrated AI-enabled predictive algorithms indicate hypoglycaemia risk within the next 30 minutes, continuously forecast how glucose levels will develop within the next two hours, and estimate the risk of nocturnal hypoglycaemia. The Accu-Chek SmartGuide solution seamlessly integrates with the Accu-Chek Care platform, offering healthcare professionals access to comprehensive therapy-relevant data provided by the CGM solution.

REGULATORY CE MARK

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 09,2024

Trinity Biotech Announces Appointment of A New CFO

Trinity Biotech plc, a biotechnology company specializing in human diagnostics and diabetes management solutions, has appointed Louise Tallon as Chief Financial Officer (CFO), effective August 2024. Des Fitzgerald, the interim CFO since December 2023, will continue in his role until late July 2024. Tallon, who currently serves as Head of Group Finance at Inizio and has a background at UDG Healthcare plc and KPMG, will also take over as Chief Accounting Officer following the departure of Simon Dunne in August 2024. The company reiterated its financial targets, aiming for $20 million in annualized EBITDASO on $75 million in revenues by Q2 2025.

View Analyst & Ambassador Comments
Go to original news
Jul 06,2024

Over-the-counter continuous glucose monitors empower diabetes patients and refine clinical insights | Viewpoint

Lucienne Ide, CEO of Rimidi, discusses the transformative impact of FDA-approved over-the-counter (OTC) continuous glucose monitors (CGMs) like Dexcom's Stelo Glucose Biosensor. This approval marks a significant advancement in diabetes management, allowing broader access to detailed glucose monitoring without the need for prescriptions or insurance, thus empowering patients. Ide highlights the shift from sporadic glucose level checks to continuous monitoring, providing comprehensive data for better disease management. Widespread adoption hinges on educational efforts to help patients and providers understand the value of CGMs. The ultimate goal is not just data collection but enhancing health management and outcomes, striving for national health equity.

#cgm

View Analyst & Ambassador Comments
Go to original news
Jul 10,2024

InventHelp Inventor Develops New Shirt for Diabetics with Insulin Pumps

An inventor from Minneapolis has developed the E Z Diabetic Shirt, a new garment designed to accommodate insulin pumps for diabetics. This patent-pending shirt offers easy access to the insulin pump, prevents the tube from pinching or snagging, and potentially extends the pump's life. The design is user-friendly and available in various styles. The invention is currently available for licensing or sale through InventHelp.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 04,2021

Carbon Health Acquires CGM-Enabled Virtual Diabetes Platform Steady Health

Carbon Health has acquired Steady Health, a diabetes platform utilizing continuous glucose monitoring (CGM) data for personalized care by top endocrinologists. This acquisition enhances Carbon Health's primary care model by integrating its clinic network with virtual and hardware-enabled services for a comprehensive healthcare experience. Financial terms were not disclosed. Additionally, Carbon Health appointed Myoung Cha, former Apple Health head, as Chief Strategy Officer (CSO) and President of Home-Based Care, and Nita Sommers, former Honor president, as Chief Growth Officer (CGO). Cha will expand device-enabled home care operations, including virtual care, remote monitoring, and home diagnostics, while also advancing the company's omnichannel care model. Sommers will grow Carbon Health’s services in mental health, pediatrics, and value-based offerings for employers and payers.

COLLABORATION MERGERS & ACQUISITION

#product & service

#cgm

#rpm

View Analyst & Ambassador Comments
Go to original news
Jun 21,2024

Dexcom's G6 CGM System Combines With AID in Netherlands

Dexcom recently announced the integration of its Dexcom G6 Continuous Glucose Monitor (CGM) system with Insulet’s Omnipod 5 Automated Insulin Delivery (AID) System for Type 1 diabetes patients in the Netherlands for an easier diabetes management experience. The combination system is intended to improve patient's quality of life by providing greater mobility without the concern of dislodging tubes. It is the first Hybrid Closed Loop (HCL) system without tubes to be authorized for use in children in the Netherlands.

PRODUCT

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 10,2024

Health for Mankind Company Launches DIABIMETRICS™

Health for Mankind Company has launched DIABIMETRICS™, a digital health platform designed to improve diabetes management in underserved communities, available on Google Play with an upcoming Apple App Store release. DIABIMETRICS™ targets high diabetes rates among African American, Hispanic, and Native American populations, offering personalized care plans using advanced algorithms and real-time data. Key features include glucose and HbA1C monitoring, virtual coaching, culturally tailored dietary guidance, medication adherence support, remote patient monitoring, and predictive analytics for early intervention. The platform also facilitates data sharing with healthcare providers, aiming to reduce complications and healthcare costs.

PRODUCT

#rpm

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 24,2024

Teladoc research shows AI-powered 'nudges' can improve diabetes members' engagement, health outcomes

Teladoc Health presented two studies at the American Diabetes Association’s 84th Scientific Sessions, demonstrating the impact of AI on diabetes management. First study aims to evaluate the effectiveness of AI-powered personalized health nudges. Over nine months, increased engagement led to significant improvements in blood sugar control. Members who received personalized nudges had a 3X increase in engagement, resulting in an additional 0.4 reduction in A1c levels (from 8.2 to 7.8). Teh second study showed  how tailored email content affects engagement with health coaches. AI-driven predictive models suggested personalized next-best actions in weekly emails to members with type 2 diabetes. Members who received these personalized recommendations were 50% more likely to engage with a health coach compared to those who received standard newsletters.

CLINICAL STUDY

#coaching

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 27,2024

Report: Dexcom cuts California jobs in manufacturing, R&D shift

Dexcom is relocating its manufacturing operations from San Diego to Mesa, Arizona, cutting over 500 San Diego positions, about 15% of its U.S. manufacturing workforce. The headquarters will stay in San Diego, which will transition into an innovation center focused on R&D, adding 30% more lab space. Affected employees can apply for roles in Arizona with relocation assistance. Dexcom’s Mesa facility has grown from 500 to 2,000 manufacturing roles in five years. The move supports Dexcom's growth and prepares for new product launches, including the Stelo CGM and G7 CGM, which now integrates with the Apple Watch and automated insulin delivery systems.

View Analyst & Ambassador Comments
Go to original news
Jul 01,2024

Global Continuous Glucose Monitoring (CGM) Market To Value at US$ 6B in 2023

The Global Continuous Glucose Monitoring Market was valued at US$ 6.32 billion in 2023 and is projected to reach US$ 13.06 billion by 2032, rising at a Compound Annual Growth Rate (CAGR) of 8.40% from 2024 to 2032, according to the publisher of the report. Company analysis features major players like Dexcom Inc., Ypsomed AG, Abbott Laboratories, and Medtronic, Inc., and includes an overview, recent developments, and revenue analysis for each.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES